2017 Press Releases

Webcast ImageWebcast
Xenon Pharmaceuticals Corporate Update (Replay)
April 26, 2017 at 6:00 a.m. PT
Xenon Pharmaceuticals Corporate Update
Wednesday, April 26, 2017 6:00 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Xenon Pharmaceuticals Inc at the 2017 Bloom Burton & Co. Healthcare Investor Conference  (Live)
May 2, 2017 at 11:00 a.m. ET
Xenon Pharmaceuticals Inc at the 2017 Bloom Burton & Co. Healthcare Investor Conference
Tuesday, May 2, 2017 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
April 28, 2017
Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
BURNABY, British Columbia, April 28, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. ... More >>
April 26, 2017
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
Phase 1 expected to begin in Q4 2017, with pharmacodynamic read-out in Q1 2018 and Phase 2 proof-of-concept clinical trial beginning in mid-2018 Conference call to be held today at 9:00 am ET BURNABY, British Columbia, April 26, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), ... More >>
March 24, 2017
Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne
Company to Hold Conference Call at 8:30 am ET Today BURNABY, British Columbia, March 24, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, ... More >>
March 8, 2017
Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update
BURNABY, British Columbia, March 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2016, and provided a corporate update for 2017. Dr. Simon Pimstone, Xenon's Pr... More >>
March 1, 2017
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2016 Financial Results and Provide Corporate Update
BURNABY, British Columbia, March 01, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2016 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2017. Xe... More >>
January 8, 2017
Xenon Pharmaceuticals Outlines Key Milestones for 2017
BURNABY, British Columbia, Jan. 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2017. Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, “As we en... More >>